Deep Brain Stimulation, Parkinson's Disease (PD)
Conditions
Keywords
Parkinson's Disease, PD, Deep Brain Stimulation, DBS, buntanetap, Open-Label, posiphen
Brief summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Detailed description
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.
Interventions
buntanetap capsules 30 mg by mouth daily
Sponsors
Annovis Bio Inc.
Duke Clinical Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All participants will receive treatment with buntanetap 30 mg daily
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE \<21 at screening. b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal. i. Female or male adults aged 40 to 85 years. ii. H\&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline. 2. Have a support person who will accompany the participant on study visits at designated times. 3. Female participants of childbearing potential\* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as: 1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation, 2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation, 3. Intrauterine device (IUD), 4. Intrauterine hormone-releasing system (IUS), 5. Bilateral tubal occlusion, 6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used), 7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant). * Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start. Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54 4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as: 1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation, 2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation, 3. IUD, 4. IUS, 5. Bilateral tubal occlusion. 5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS. 6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications. 1. Standard of care anti-parkinsonian medication, 2. Cholinesterase inhibitors and/or memantine medication, 3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening, 4. Mood-stabilizing psychotropic agents including, but not limited to, lithium, 7. Adequate visual and hearing ability (physical ability to perform all the study assessments). 8. Good general health with no disease expected to interfere with the study.
Exclusion criteria
1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of buntanetap | 36-months of treatment | Safety assessments of participants with PD receiving treatment with buntanetap |
| Adverse Events (AE) | 36-months of treatment | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention |
| Treatment Emergent Adverse Events (TEAE) | 36-months of treatment | TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state |
| Serious Adverse Events (SAE) | 36-months of treatment | SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly |
Countries
United States
Contacts
CONTACTSarah MacCallum, BSN RN
CONTACTAlexander Morin, PhD
PRINCIPAL_INVESTIGATORLaurie Sanders, Ph.D.
Duke Clinical Research Institute
Outcome results
None listed